ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

F3

coagulation factor III, tissue factor · also CD142, TF · CD molecules

6 programs in company-led studies act on F3, from 6 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
tisotumab vedotinrulePfizer–phase 4112 running–NCIt
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciences–phase 333 running–NCIt
Anti-TF Antibody-drug Conjugate MRG004AruleLepu Biopharma–phase 321 running–NCIt
SHR-4375Jiangsu HengRui Medicine–phase 222 running–the company's pipeline
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004ruleSutro Biopharma–phase 111 running–NCIt
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixis–phase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.